441354-26-3

Upstream product

• 98-17-9 3-Trifluoromethylphenol 
• 459-57-4 4-fluorobenzaldehyde 

Downstream Products

• 1380429-68-4 3-(4-(3-(trifluoromethyl)phenoxy)phenyl)propanenitrile 
• 1369258-34-3 2-(4-(3-(trifluoromethyl)phenoxy)phenyl)ethanol 
• 1380427-21-3 1-methyl-5-(pyrimidin-5-ylmethyl)-2-(4-(3-(trifluoromethyl)phenoxy)phenethyl)pyrimidin-4(1H)-one 
• 1380427-19-9 5-(pyrimidin-5-ylmethyl)-2-(4-(3-(trifluoromethyl)phenoxy)phenethyl)pyrimidin-4(1H)-one 
• 1380427-18-8 5-ethyl-2-(4-(3-(trifluoromethyl)phenoxy)phenethyl)pyrimidin-4(1H)-one 
• 1380429-69-5 3-(4-(3-(trifluoromethyl)phenoxy)phenyl)propanimidamide 
• 1380429-45-7 1-(trifluoromethyl)-3-(4-vinylphenoxy)benzene 
• 1380429-67-3 3-(4-(3-(trifluoromethyl)phenoxy)phenyl)acrylonitrile 
• 75053-80-4 P-(α,α,α-trifluoro-m-tolyloxy)phenol 
• 1369255-57-1 (4-(3-(trifluoromethyl)phenoxy)phenyl)methanol 

Relevant academic research and scientific papers

BICYCLIC PYRIMIDONE COMPOUNDS

The present invention relates to novel bicyclic pyrimidone compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease.

PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP - PLA2

The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease, and/or diabetic macular edema (I).

TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES

The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease, and/or diabetic macular edema.

Synthesis and structure-activity relationships of 4-pyridones as potential antimalarials

A series of diaryl ether substituted 4-pyridones have been identified as having potent antimalarial activity superior to that of chloroquine against Plasmodium falciparum in vitro and murine Plasmodium yoelii in vivo. These were derived from the anticoccidial drug clopidol through a systematic study of the effects of varying the side chain on activity. Relative to clopidol the most active compounds show > 500-fold improvement in IC50 for inhibition of P. falciparum in vitro and about 100-fold improvement with respect to ED50 against P. yoelii in mice. These compounds have been shown elsewhere to act selectively by inhibition of mitochondrial electron transport at the cytochrome bc1 complex.

AMINO ALCOHOL DERIVATIVE, ADDITION SALT THEREOF, AND IMMUNOSUPPRESSANT

An amino alcohol derivative represented by the following general formula (1) (for example, (±)-2-amino-5-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-2-methylpentane-1-ol) exhibits strong immunosuppressive effect while causing less side effects:

AMINOPHOSPHONIC ACID DERIVATIVES, ADDITION SALTS THEREOF AND S1P RECEPTOR MODULATORS

Aminophosphonic acid derivatives (e.g., 2-amino-5-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-2-methylpentylphosphonate monoester) are represented by the following general formula (1) : and act as effective S1P receptor modulators while posing less side effects.

DIARYL ETHER DERIVATIVE, ADDITION SALT THEREOF, AND IMMUNOSUPPRESSANT

The present invention provides diaryl ether derivatives that exhibit significant immunosuppressive effects with less side effects. The diaryl derivatives of the present invention are represented by the following general formula (1): ???one example is 2-amino-2-[4-(3-benzyloxyphenoxy)-2-chlorophenyl)propyl-1,3-propanediol.